Alteration in Nature of Cluster Headache During Subcutaneous Administration of Sumatriptan

Hering-Hanit, Rachel

doi:10.1046/j.1526-4610.2000.00007.x

Cited by 21 publications

(16 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5 The development of a chronic daily headache (CDH) has been described in 3 patients with CH using subcutaneous (SC) sumatriptan 6 mg within the recommended dosing schedule of a maximum of two injections per day. 6 An increase in CH attack frequency has been described by three authors in patients using long-term treatment with SC sumatriptan. [7][8][9] Other authors have given accounts of the uneventful overuse of sumatriptan by CH patients, [10][11][12] and MOH in association with CH is not a widely recognized problem.…”

mentioning

confidence: 95%

Medication-overuse headache in patients with cluster headache

Paemeleire

Bahra²,

Evers³

et al. 2006

Neurology

151

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 95%

Medication-overuse headache in patients with cluster headache

Paemeleire

Bahra²,

Evers³

et al. 2006

Neurology

151

View full text Add to dashboard Cite

show abstract

“…Moreover, the drug was less effective for chronic cluster headache. In fact, there is only one clear report in the literature asserting that the frequency of attacks in CH is altered during subcutaneous administration of sumatriptan [13]: in 1999, Hering-Hanit described 4 episodic CH patients treated with the drug for the first time, and who developed a dramatic increase in the frequency of their attacks. Three of them developed chronic daily headache after being put on this medication for 3-4 weeks, and two experienced a longer CH period than previously.…”

Section: Discussionmentioning

confidence: 99%

Does repeated subcutaneous administration of sumatriptan produce an unfavorable evolution in cluster headache?

et al. 2004

View full text Add to dashboard Cite

Cluster headache (CH) is one of the most painful primitive headaches that exists. Since 1991, the subcutaneous administration of sumatriptan (SCS) in the treatment of acute attacks has proved to be rapid and effective. Moreover, SCS has an excellent safety-efficacy ratio. To date, there is no information on the modalities of SCS use by CH patients, and on its possible overuse. In fact, some patients have noticed that the use of this drug on a regular basis modifies the evolution of attacks. We retrospectively studied, in 67 patients admitted for CH, the modalities of self-administering SCS the subjective feeling of medication overuse and its repercussions on attacks. A total of 47 patients used exclusively SCS as an acute treatment, 30 of whom had used more than two injections daily. Four patients whose use of SCS was the highest had also been drug addicts. Twenty-two patients using exclusively SCS thought that sumatriptan could have modified the evolution of attacks: 20 patients thought that the attacks occurred more frequently; 11 commented that the attacks became more intense, and the remaining 11 patients stated that sumatriptan had become less efficient. In CH, overuse of sumatriptan could aggravate the evolution of attacks. Further research is needed to corroborate this argument.

show abstract

“…Hering noted that the use of daily injectable sumatriptan in four cluster patients led to a marked increase in the frequency of cluster attacks 3-4 weeks after initiating treatment [5]. In three patients, the character of the cluster headache changed while two patients experienced prolongation of their cluster headache period.…”

Section: Sumatriptanmentioning

confidence: 98%